{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:27:44Z","timestamp":1794252464046,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.lungcan.2024.108040","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T02:44:22Z","timestamp":1732502662000},"page":"108040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations"],"prefix":"10.1016","volume":"199","author":[{"given":"Tejas","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Yoder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Stalker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara L.","family":"Aisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina E.","family":"Marmarelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bennati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Navani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2024.108040_b0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2017","journal-title":"New Engl J Med."},{"key":"10.1016\/j.lungcan.2024.108040_b0010","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum\u2013pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108040_b0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000805","article-title":"Resistance mechanisms to osimertinib and emerging therapeutic strategies in non-small cell lung cancer","volume":"34","author":"Zeng","year":"2022","journal-title":"Curr. Opin. Oncol.."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108040_b0020","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108040_b0025","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep. Med.."},{"issue":"18","key":"10.1016\/j.lungcan.2024.108040_b0030","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-20-2811","article-title":"Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer","volume":"81","author":"Kashima","year":"2021","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2024.108040_b0035","first-page":"1527","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-Positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"J. Am. Med. Assoc. Onc."},{"issue":"10","key":"10.1016\/j.lungcan.2024.108040_b0040","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/annonc\/mdx396","article-title":"Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)","volume":"8","author":"Martinez-Marti","year":"2017","journal-title":"Ann Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.108040_b0045","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108040_b0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.lungcan.2024.108040_b0055","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.108040_b0060","article-title":"Brief report: clinical response, toxicity, and resistance mechanisms to osimertinib plus MET inhibitors in patients with EGFR-mutant MET-amplified NSCLC","volume":"4","author":"Wang","year":"2024","journal-title":"JTO Clin Res Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108040_b0065","article-title":"The efficacy and safety of treating acquired MET resistance through combinations of parent and MET tyrosine kinase inhibitors in patients with metastatic oncogene-driven NSCLC","volume":"5","author":"Patil","year":"2024","journal-title":"JTO Clin Res Rep."},{"issue":"9","key":"10.1016\/j.lungcan.2024.108040_b0070","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2024.108040_b0075","doi-asserted-by":"crossref","unstructured":"Mok TS, Wu YL, Ahn MJ, et al; Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 376(7):629-640. doi: 10.1056\/NEJMoa1612674.","DOI":"10.1056\/NEJMoa1612674"},{"key":"10.1016\/j.lungcan.2024.108040_b0080","doi-asserted-by":"crossref","unstructured":"Mok TS, Nakagawa K, Park K, et al: Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722. J Clin Oncol. 42(11):1252-1264.doi: 10.1200\/JCO.23.01017.","DOI":"10.1200\/JCO.23.01017"},{"key":"10.1016\/j.lungcan.2024.108040_b0085","doi-asserted-by":"crossref","unstructured":"Yang JCH, Lee DH, Lee JS, et al: Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2013resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J Clin Oncol. 2024; [Epub \u2013 ahead of print]. doi: 10.1200\/JCO.23.02747.","DOI":"10.1200\/JCO.23.02747"},{"issue":"1","key":"10.1016\/j.lungcan.2024.108040_b0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2024.108040_b0095","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/curroncol31050182","article-title":"Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib","volume":"31","author":"Gibson","year":"2024","journal-title":"Curr. Oncol.."},{"key":"10.1016\/j.lungcan.2024.108040_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107856","article-title":"Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC","volume":"193","author":"Saw","year":"2024","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2024.108040_b0105","article-title":"Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib","author":"Robinson","year":"2024","journal-title":"Clin Lung Cancer."},{"key":"10.1016\/j.lungcan.2024.108040_b0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2021.01.010","article-title":"Combining osimertinib with chemotherapy in EGFR-Mutant NSCLC at progression","volume":"22","author":"White","year":"2021","journal-title":"Clin Lung Cancer."},{"key":"10.1016\/j.lungcan.2024.108040_b0115","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2017.73.9250","article-title":"Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation\u2013Positive Non\u2013Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses","volume":"35","author":"Mok","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2024.108040_b0120","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-12-0357","article-title":"The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations","volume":"18","author":"Heon","year":"2012","journal-title":"Clin Can Res."},{"issue":"12","key":"10.1016\/j.lungcan.2024.108040_b0125","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J Thorac Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108040_b0130","article-title":"Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non\u2013small cell lung cancer in patients with brain metastases The GAP BRAIN open-label, randomized, multicenter, Phase 3 study","volume":"6","author":"Hou","year":"2023","journal-title":"J. Am. Med. Assoc. Netw Open."},{"key":"10.1016\/j.lungcan.2024.108040_b0135","doi-asserted-by":"crossref","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, et al: CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. [Epub \u2013 ahead of print]. doi: 10.1200\/JCO.2018.78.3118.","DOI":"10.1200\/JCO.2018.78.3118"},{"issue":"12","key":"10.1016\/j.lungcan.2024.108040_b0140","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.jtho.2023.08.017","article-title":"Central nervous system outcomes of lazertinib versus gefitinib in EGFR-Mutated advanced NSCLC: a LASER301 subset analysis","volume":"18","author":"Soo","year":"2023","journal-title":"J Thorac Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2024.108040_b0145","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.lungcan.2024.108040_b0150","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.108040_b0155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/neuonc\/nos004","article-title":"Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma","volume":"14","author":"Bailon","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.lungcan.2024.108040_b0160","first-page":"386","article-title":"Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M\u2013mutated non\u2013small cell lung cancer previously treated with epidermal growth factor receptor\u2013tyrosine kinase inhibitor","volume":"7","author":"Akamatsu","year":"2021","journal-title":"J. Am. Med. Assoc. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2024.108040_b0165","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.lungcan.2024.108040_b0170","doi-asserted-by":"crossref","unstructured":"Yoh K, Terufumi K, Nakahara Y, et al: OSIRAM-1\/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer [abstract 8613]. Abstract presented at ASCO Annual Meeting; May 31 \u2013 June 4, 2024; Chicago, IL, USA. doi: https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8613.","DOI":"10.1200\/JCO.2024.42.16_suppl.8613"},{"key":"10.1016\/j.lungcan.2024.108040_b0175","doi-asserted-by":"crossref","unstructured":"Le X, Patel JD, Shum E, et al: A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial). J Clin Oncol. 2024; [Epub \u2013 ahead of print]. doi: https:\/\/doi.org\/10.1200\/JCO.24.00533.","DOI":"10.1200\/JCO.24.00533"},{"key":"10.1016\/j.lungcan.2024.108040_b0180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer."},{"key":"10.1016\/j.lungcan.2024.108040_b0185","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:51:34Z","timestamp":1756860694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224005749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"alternative-id":["S0169500224005749"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.108040","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.108040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108040"}}